Adjuvant Chemotherapy for Colorectal Cancer - ppt video online download
Duration of adjuvant therapy for stage III colon cancer: No longer one size fits all | The Bulletin
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial - Annals of Oncology
Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients - Clinical Colorectal Cancer
A Report from ASCO-GI 2008 and ASCO 2007 Up-to-Date Review of the Treatment of Adjuvant Colorectal Cancer Axel Grothey, MD Professor of Oncology Mayo Clinic. - ppt download
Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up. - ppt download
Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial | British Journal of Cancer
Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions
Instant Oncology: SCOT - Clinical Oncology
Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial | British Journal of Cancer
Adjuvant Chemotherapy for Stage II and III Colon Cancer: When, How, and for Whom
Prognostic factors of adjuvant chemotherapy discontinuation among stage III colon cancer patients: A survey of medical oncologists and a systematic review and meta‐analysis - Boyne - 2020 - Cancer Medicine - Wiley Online Library
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials - The Lancet Oncology
MOSAIC Data Support FOLFOX- 4 Use in High-Risk Stage II Colon Cancer
Kaplan-Meier estimates of overall survival (OS) in the intent-to-treat... | Download Scientific Diagram
PPT - Adjuvant Chemotherapy for Colorectal Cancer PowerPoint Presentation - ID:4488184
MOSAIC Data Support FOLFOX- 4 Use in High-Risk Stage II Colon Cancer
PDF) Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
Deciding the Duration of Adjuvant Chemotherapy in a Patient With Stage III Colon Cancer: When Can Less Be More?
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer | NEJM
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study | Journal of
Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience | Cancer Communications | Full Text
Cost-Effectiveness of Adjuvant FOLFOX Therapy for Stage III Colon Cancer in Japan Based on the MOSAIC Trial - Value in Health
